BackSunshine Biopharma- Warrants (15/02/2027) Overview

Sunshine Biopharma- Warrants (15/02/2027) Total Liabilities

Sunshine Biopharma- Warrants (15/02/2027)'s total liabilities is $5.2M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$5.22M
↑ 720.11% YoYΔ $4.59M vs prior year quarter

Peer trimmed avg / median

Loading

Sunshine Biopharma- Warrants (15/02/2027) Total Liabilities History

Loading

Sunshine Biopharma- Warrants (15/02/2027) vs. peers: Total Liabilities Comparison

Loading

Sunshine Biopharma- Warrants (15/02/2027) Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sunshine Biopharma- Warrants (15/02/2027) (SBFMW) FAQ

Sunshine Biopharma- Warrants (15/02/2027)'s total liabilities stands at $5.2M as of September 2026. That compares with $640K in the prior-year period — up 720.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Sunshine Biopharma- Warrants (15/02/2027) reported $5.2M in total liabilities versus $640K a year earlier — a 720.1% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $640K in the prior-year period — up 720.1% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Sunshine Biopharma- Warrants (15/02/2027)'s total liabilities evolved across reporting periods, while the comparison chart places SBFMW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Sunshine Biopharma- Warrants (15/02/2027)'s reading of $5.2M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.